Table 1. Toca 511 and Toca FC OS. K-M, Kaplan-Meier.
PopulationnMedian survival, 95% CI (months)
Efficacy evaluable—HGG4313.6 (10.8–20.0)
Efficacy evaluable—HGG, first and second recurrence3214.4 (11.3–32.3)
Glioblastoma efficacy evaluable3511.6 (9.2–14.6)
Glioblastoma efficacy evaluable—first and second recurrence2713.6 (11.1–20.0)
Landmark OS for efficacy evaluable—HGG43K-M survival rate
OS687.9%
OS972.4%
OS1252.5%
OS2431.6%